Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease

Trends in Molecular Medicine

Volumn 23, Issue 4, 2017, Pages 362-374

  Nielsen, Ole Haagen ^a   Li, Yuan ^a   Johansson Lindbom, Bengt ^b,c   Coskun, Mehmet ^a,d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

inflammatory bowel disease; receptor modulators; small molecules; sphingosine 1 phosphate; therapy

Indexed keywords

AMISELIMOD; ETRASIMOD; LYASE; OZANIMOD; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; INDAN DERIVATIVE; LYSOPHOSPHOLIPID; MOLECULAR LIBRARY; OXADIAZOLE DERIVATIVE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

CHRONIC INFLAMMATION; HUMAN; INFLAMMATORY BOWEL DISEASE; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; INFLAMMATORY BOWEL DISEASES; MOLECULAR LIBRARY; THERAPEUTIC USE;

ANIMALS; DRUG DISCOVERY; HUMANS; INDANS; INFLAMMATORY BOWEL DISEASES; LYSOPHOSPHOLIPIDS; MOLECULAR TARGETED THERAPY; OXADIAZOLES; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; SPHINGOSINE;

EID: 85014671116     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2017.02.002     Document Type: Review

References (115)

1. 1 Dubinsky, M., Braun, J., Diagnostic and prognostic microbial biomarkers in inflammatory bowel diseases. Gastroenterology 149 (2015), 1265–1274.
2. 2 Kostic, A.D., et al. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146 (2014), 1489–1499.
3. 3 Danese, S., Fiocchi, C., Ulcerative colitis. N. Engl. J. Med. 365 (2011), 1713–1725.
4. 4 Baumgart, D.C., Sandborn, W.J., Crohn's disease. Lancet 380 (2012), 1590–1605.
5. 5 Kaplan, G.G., Jess, T., The changing landscape of inflammatory bowel disease: East meets West. Gastroenterology 150 (2016), 24–26.
6. 6 Molodecky, N.A., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142 (2012), 46–54.
7. 7 Larsen, S., et al. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann. Med. 42 (2010), 97–114.
8. 8 Abraham, C., Cho, J.H., Inflammatory bowel disease. N. Engl. J. Med. 361 (2009), 2066–2078.
9. 9 Ananthakrishnan, A.N., Epidemiology and risk factors for IBD. Nat. Rev. Gastroenterol. Hepatol. 12 (2015), 205–217.
10. 10 Beaugerie, L., Itzkowitz, S.H., Cancers complicating inflammatory bowel disease. N. Engl. J. Med. 372 (2015), 1441–1452.
11. 11 Ford, A.C., et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am. J. Gastroenterol. 106 (2011), 590–599.
12. 12 Nielsen, O.H., Munck, L.K., Drug insight: aminosalicylates for the treatment of IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 4 (2007), 160–170.
13. 13 Nielsen, O.H., et al. The role and advances of immunomodulator therapy for inflammatory bowel disease. Expert. Rev. Gastroenterol. Hepatol. 9 (2015), 177–189.
14. 14 Nielsen, O.H., Ainsworth, M.A., Tumor necrosis factor inhibitors for inflammatory bowel disease. N. Engl. J. Med. 369 (2013), 754–762.
15. 15 Coskun, M., et al. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol. Sci. 38 (2017), 127–142.
16. 16 Danese, S., et al. Biologic agents for IBD: practical insights. Nat. Rev. Gastroenterol. Hepatol. 12 (2015), 537–545.
17. 17 Olesen, C.M., et al. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacol. Ther. 159 (2016), 110–119.
18. 18 Suh, J.H., Saba, J.D., Sphingosine-1-phosphate in inflammatory bowel disease and colitis-associated colon cancer: the fat's in the fire. Transl. Cancer Res. 4 (2015), 469–483.
19. 19 Cuvillier, O., et al. Effect of a therapeutic sphingosine 1-phosphate antibody on intratumoral hypoxia and standard chemotherapy in a preclinical model of prostate cancer. J. Clin. Oncol., 30, 2012, 223.
20. 20 Zhang, L., et al. Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI-resistant renal cancer. Clin. Cancer Res. 21 (2015), 1925–1934.
21. 21 Sabbadini, R.A., Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. Br. J. Pharmacol. 162 (2011), 1225–1238.
22. 22 Guerrero, M., et al. Sphingosine 1-phosphate receptor 1 agonists: a patent review (2013–2015). Expert. Opin. Ther. Pat. 26 (2016), 455–470.
23. 23 Mao-Draayer, Y., et al. The sphingosine-1-phosphate receptor: a novel therapeutic target for multiple sclerosis and other autoimmune diseases. Clin. Immunol. 175 (2016), 10–15.
24. 24 Proia, R.L., Hla, T., Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J. Clin. Invest. 125 (2015), 1379–1387.
25. 25 Vesper, H., et al. Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J. Nutr. 129 (1999), 1239–1250.
26. 26 Abdel Hadi, L., et al. Fostering inflammatory bowel disease: sphingolipid strategies to join forces. Mediators Inflamm., 2016, 2016, 3827684.
27. 27 Gault, C.R., et al. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv. Exp. Med Biol. 688 (2010), 1–23.
28. 28 Vogt, D., Stark, H., Therapeutic strategies and pharmacological tools influencing S1P signaling and metabolism. Med. Res. Rev. 37 (2017), 3–51.
29. 29 Liu, H., et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J. Biol. Chem. 275 (2000), 19513–19520.
30. 30 Igarashi, N., et al. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J. Biol. Chem. 278 (2003), 46832–46839.
31. 31 Pitson, S.M., et al. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 22 (2003), 5491–5500.
32. 32 Pappu, R., et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 316 (2007), 295–298.
33. 33 Mandala, S.M., Sphingosine-1-phosphate phosphatases. Prostaglandins 64 (2001), 143–156.
34. 34 Maceyka, M., Spiegel, S., Sphingolipid metabolites in inflammatory disease. Nature 510 (2014), 58–67.
35. 35 Strub, G.M., et al. Extracellular and intracellular actions of sphingosine-1-phosphate. Adv. Exp. Med. Biol. 688 (2010), 141–155.
36. 36 Degagne, E., Saba, J.D., S1pping fire: sphingosine-1-phosphate signaling as an emerging target in inflammatory bowel disease and colitis-associated cancer. Clin. Exp. Gastroenterol. 7 (2014), 205–214.
37. 37 Aguilar, A., Saba, J.D., Truth and consequences of sphingosine-1-phosphate lyase. Adv. Biol. Regul. 52 (2012), 17–30.
38. 38 Schwab, S.R., et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309 (2005), 1735–1739.
39. 6 plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am. J. Gastroenterol. 98 (2003), 112–117.
40. −/− model of inflammatory bowel disease. J. Nutr. Biochem. 24 (2013), 2138–2143.
41. 41 Oskouian, B., et al. Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancer. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 17384–17389.
42. 42 Kohno, M., et al. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol. Cell. Biol. 26 (2006), 7211–7223.
43. 43 Hla, T., Dannenberg, A.J., Sphingolipid signaling in metabolic disorders. Cell Metab. 16 (2012), 420–434.
44. 44 Spiegel, S., Milstien, S., The outs and the ins of sphingosine-1-phosphate in immunity. Nat. Rev. Immunol. 11 (2011), 403–415.
45. 45 Fyrst, H., Saba, J.D., An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat. Chem. Biol. 6 (2010), 489–497.
46. 46 Blaho, V.A., Hla, T., An update on the biology of sphingosine 1-phosphate receptors. J. Lipid Res. 55 (2014), 1596–1608.
47. 47 Brinkmann, V., Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther. 115 (2007), 84–105.
48. 48 Simmons, S., Ishii, M., Sphingosine-1-phosphate: a master regulator of lymphocyte egress and immunity. Arch. Immunol. Ther. Exp. (Warsz.) 62 (2014), 103–115.
49. 49 Sanchez, T., Hla, T., Structural and functional characteristics of S1P receptors. J. Cell. Biochem. 92 (2004), 913–922.
50. 50 Wang, C., et al. Systemic distribution, subcellular localization and differential expression of sphingosine-1-phosphate receptors in benign and malignant human tissues. Exp. Mol. Pathol. 97 (2014), 259–265.
51. 51 Matloubian, M., et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427 (2004), 355–360.
52. 52 Cyster, J.G., Schwab, S.R., Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol. 30 (2012), 69–94.
53. 53 Olivera, A., et al. Shaping the landscape: metabolic regulation of S1P gradients. Biochim. Biophys. Acta 1831 (2013), 193–202.
54. 54 Venkataraman, K., et al. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ. Res. 102 (2008), 669–676.
55. 55 Pham, T.H., et al. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J. Exp. Med. 207 (2010), 17–27.
56. 56 Kharel, Y., et al. Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate. Biochem. J. 440 (2011), 345–353.
57. 57 Baeyens, A., et al. Exit strategies: S1P signaling and T cell migration. Trends Immunol. 36 (2015), 778–787.
58. i-coupled receptors to promote T cell egress. Immunity 28 (2008), 122–133.
59. 59 Shiow, L.R., et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440 (2006), 540–544.
60. 60 McConnell, I., et al. Lymphocyte traffic through lymph nodes during cell shutdown. Ciba Found. Symp. 71 (1980), 167–195.
61. 61 Cinamon, G., et al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat. Immunol. 5 (2004), 713–720.
62. 62 Finlay, D., Cantrell, D.A., Metabolism, migration and memory in cytotoxic T cells. Nat. Rev. Immunol. 11 (2011), 109–117.
63. 63 Snider, A.J., et al. A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J. 23 (2009), 143–152.
64. 64 Maines, L.W., et al. Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig. Dis. Sci. 53 (2008), 997–1012.
65. 65 Maines, L.W., et al. Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease. Inflammopharmacology 18 (2010), 73–85.
66. 66 Karuppuchamy, T., et al. Sphingosine-1-phosphate receptor-1 (S1P) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease. Mucosal Immunol. 10 (2017), 161–171.
67. 67 Duan, R.D., Physiological functions and clinical implications of sphingolipids in the gut. J. Dig. Dis. 12 (2011), 60–70.
68. 1 localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity. J. Lipid Res. 54 (2013), 843–851.
69. 69 Lepine, S., et al. Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced autophagy. Cell Death Differ. 18 (2011), 350–361.
70. 70 Rivera, J., et al. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat. Rev. Immunol. 8 (2008), 753–763.
71. 71 Lee, H., et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat. Med. 16 (2010), 1421–1428.
72. 72 Liang, J., et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 23 (2013), 107–120.
73. 73 Naser, S.A., et al. Role of ATG16L, NOD2 and IL23R in Crohn's disease pathogenesis. World J. Gastroenterol. 18 (2012), 412–424.
74. 74 Alvarez, S.E., et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 465 (2010), 1084–1088.
75. 75 Salem, M., et al. Muramyl dipeptide responsive pathways in Crohn's disease: from NOD2 and beyond. Cell. Mol. Life Sci. 70 (2013), 3391–3404.
76. 76 Pelletier, D., Hafler, D.A., Fingolimod for multiple sclerosis. N. Engl. J. Med. 366 (2012), 339–347.
77. 77 Daniel, C., et al. FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions. Mol. Immunol. 44 (2007), 3305–3316.
78. + regulatory T cells. J. Immunol. 178 (2007), 2458–2468.
79. 79 Deguchi, Y., et al. The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice. Oncol. Rep. 16 (2006), 699–703.
80. 80 Mizushima, T., et al. Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis. Inflamm. Bowel. Dis. 10 (2004), 182–192.
81. 81 Cucak, H., et al. Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity 31 (2009), 491–501.
82. 82 Camm, J., et al. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am. Heart J. 168 (2014), 632–644.
83. 83 Faber, H., et al. Prolonged and symptomatic bradycardia following a single dose of fingolimod. Mult. Scler. 19 (2013), 126–128.
84. 84 Espinosa, P.S., Berger, J.R., Delayed fingolimod-associated asystole. Mult. Scler. 17 (2011), 1387–1389.
85. 85 Sandborn, W.J., et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N. Engl. J. Med. 374 (2016), 1754–1762.
86. 86 Cohen, J.A., et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, Phase 2 trial. Lancet Neurol. 15 (2016), 373–381.
87. 5) agonist with autoimmune disease-modifying activity. Br. J. Pharmacol. 173 (2016), 1778–1792.
88. 88 Song, J., et al. A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. J. Pharmacol. Exp. Ther. 324 (2008), 276–283.
89. 89 Gergely, P., et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br. J. Pharmacol. 167 (2012), 1035–1047.
90. 90 Gonzalez-Cabrera, P.J., S1P signaling: new therapies and opportunities. F1000Prime Rep., 6, 2014, 109.
91. 91 Buzard, D.J., et al. Discovery of APD334: design of a clinical stage functional antagonist of the sphingosine-1-phosphate-1 receptor. ACS Med. Chem. Lett. 5 (2014), 1313–1317.
92. 92 Subei, A.M., Cohen, J.A., Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs 29 (2015), 565–575.
93. 93 Habtezion, A., et al. Leukocyte trafficking to the small intestine and colon. Gastroenterology 150 (2016), 340–354.
94. 4. FASEB J. 24 (2010), 4701–4710.
95. 95 Garcia, J.G., et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J. Clin. Invest. 108 (2001), 689–701.
96. 96 Liu, Y., et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest. 106 (2000), 951–961.
97. 3, respectively, regulate lymphocyte recirculation and heart rate. J. Biol. Chem. 279 (2004), 13839–13848.
98. 98 Zhang, G., et al. Critical role of sphingosine-1-phosphate receptor 2 (S1PR2) in acute vascular inflammation. Blood 122 (2013), 443–455.
99. 2 receptor subtype. Cardiovasc. Res. 82 (2009), 221–228.
100. 3 receptors. Drug News Perspect. 17 (2004), 365–382.
101. 3 receptor antagonist. Mol. Pharmacol. 77 (2010), 704–713.
102. 3. Circ. Res. 96 (2005), 913–920.
103. 3. J. Clin. Invest. 113 (2004), 569–581.
104. 4 receptor mediates S1P-induced vasoconstriction in normotensive and hypertensive rat lungs. Pulm. Circ. 1 (2011), 399–404.
105. 1 overrides regulatory T cell-mediated immune suppression through Akt–mTOR. Nat. Immunol. 10 (2009), 769–777.
106. reg cells. Nat. Immunol. 11 (2010), 1047–1056.
107. H17-mediated autoimmune neuroinflammation. Nat. Immunol. 14 (2013), 1166–1172.
108. 2 maintains the homeostasis of germinal center B cells and promotes niche confinement. Nat. Immunol. 12 (2011), 672–680.
109. 109 Wang, X., et al. Follicular dendritic cells help establish follicle identity and promote B cell retention in germinal centers. J. Exp. Med. 208 (2011), 2497–2510.
110. H17-cell differentiation in a murine model. FASEB J. 25 (2011), 4024–4036.
111. 111 Walzer, T., et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat. Immunol. 8 (2007), 1337–1344.
112. 5 inhibits oligodendrocyte progenitor migration. FASEB J. 21 (2007), 1503–1514.
113. 113 Czeloth, N., et al. Sphingosine-1-phosphate mediates migration of mature dendritic cells. J. Immunol. 175 (2005), 2960–2967.
114. 114 Idzko, M., et al. Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J. 16 (2002), 625–627.
115. 115 Mehling, M., et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 75 (2010), 403–410.